drugset / Trial / NCT04501029
A Study of Gimatecan (ST1481) in Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
This phase Ib/II clinical trial studies the safety and effect of Gimatecan in small cell lung cancer patients who failed the first-line standard platinum-containing chemotherapy. The chemotherapy will be given every four weeks.
Timeline
- Start
- 2020-10-01
- Primary completion
- 2022-10-01
- Completion
- 2023-10-01
Publications
- Results Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist. 2009 Oct;14(10):986-94. doi: 10.1634/theoncologist.2009-0026. Epub 2009 Oct 9.
- Results Owonikoko TK, Behera M, Chen Z, Bhimani C, Curran WJ, Khuri FR, Ramalingam SS. A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancer. J Thorac Oncol. 2012 May;7(5):866-72. doi: 10.1097/JTO.0b013e31824c7f4b.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gimatecan | Small molecule | 0.4 mg/m2 | Oral |
| Subject | Gimatecan | Small molecule | 0.6 mg/m2 | Oral |
| Subject | Gimatecan | Small molecule | 0.8 mg/m2 | Oral |